Trial Profile
Phase II Study of Bevacizumab and Temozolomide in Elderly Patients With Newly-Diagnosed Glioblastoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- 29 Feb 2024 Status changed from active, no longer recruiting to completed.
- 14 Feb 2023 Planned End Date changed from 8 Feb 2024 to 8 Feb 2025.
- 14 Feb 2023 Planned primary completion date changed from 8 Feb 2023 to 8 Feb 2024.